{
    "root": "34eec0b8-ef99-4d69-bd3f-da1373da2e49",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "RAPAFLO",
    "value": "20201201",
    "ingredients": [
        {
            "name": "SILODOSIN",
            "code": "CUZ39LUY82"
        }
    ],
    "indications": "RAPAFLO®, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [\n                     see CLINICAL STUDIES (\n                     \n                        14\n                     \n                     )\n                     ]\n                     . RAPAFLO is not indicated for the treatment of hypertension.",
    "contraindications": "8 mg capsules taken orally once daily with a meal. ( 2.1 ) 4 mg capsules taken orally once daily with a meal for those with moderate renal impairment [Creatinine Clearance (CCr) 30-50 mL/min]. ( 2.2 )",
    "warningsAndPrecautions": "White, opaque, hard gelatin 8 mg capsules\n                     . Cap is imprinted with “WATSON 152” in green. Body is imprinted with “8 mg” in green. 8 mg capsules are supplied in unit of use HDPE bottles of:\n                  \n                     30 capsules (NDC\n                         0023-6142-30)\n                     \n                     90 capsules (NDC\n                         0023-6142-90)\n                  \n                  Bottles of 30 and 90 capsules are supplied with child-resistant closures.\n                  \n                     White, opaque, hard gelatin 4 mg capsules\n                     . Cap is imprinted with “WATSON 151” in gold. Body is imprinted with “4 mg” in gold. 4 mg capsules are supplied in unit of use HDPE bottles of:\n                  \n                     30 capsules (NDC\n                         0023-6147-30)\n                  \n                  Bottles of 30 capsules are supplied with child-resistant closures.\n                  \n                     Storage\n                  \n                  Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). [See USP controlled room temperature.] Protect from light and moisture.\n                  \n                     Keep out of reach of children.",
    "adverseReactions": "Severe renal impairment (CCr < 30 mL/min)\n                     \n                     Severe hepatic impairment (Child-Pugh score > 10)\n                     \n                     Concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) [\n                        see DRUG INTERACTIONS (\n                        \n                           7.1\n                        \n                        )\n                        ]\n                        \n                     \n                     Patients with a history of hypersensitivity to silodosin or any of the ingredients of RAPAFLO [\n                        see ADVERSE REACTIONS (\n                        \n                           6.2\n                        \n                        ) and DESCRIPTION (\n                        \n                           11\n                        )]"
}